Sign In
Buy CADL
$8.80
+0.380 (+4.51%)
At Close: Jun 03, 2026
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
12:11pm, Tuesday, 28'th May 2024
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
Candel (CADL) Reports Upbeat Data From Lung Cancer Study
12:46pm, Friday, 24'th May 2024
Candel's (CADL) CAN-2409 prolongs overall survival in a phase II study for treating patients with advanced non-small cell lung cancer who are non-responsive to immune checkpoint inhibitor therapy.
NEEDHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
08:00am, Wednesday, 22'nd May 2024
NEEDHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
08:00am, Monday, 20'th May 2024
Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC Management and scientific/medical thought leaders to discuss
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
08:00am, Tuesday, 14'th May 2024
NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
08:00am, Thursday, 25'th Apr 2024
NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi
Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
04:35pm, Monday, 15'th Apr 2024
Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
11:01am, Friday, 12'th Apr 2024
Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
09:00am, Thursday, 11'th Apr 2024
NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi
NEEDHAM, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
01:11pm, Friday, 05'th Apr 2024
Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
01:11pm, Friday, 05'th Apr 2024
Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.
Candel Therapeutics stock jumps as pancreatic cancer treatment shows promise
08:56am, Friday, 05'th Apr 2024
Shares of Candel Therapeutics Inc. CADL, +280.95% climbed 15% early Friday after the company released new data from a trial of its experimental cancer treatment.
Candel Therapeutics stock soars 30%: find out more
08:28am, Friday, 05'th Apr 2024
Candel Therapeutics Inc is up roughly 30% in premarket on Friday after reporting positive interim data for its experimental treatment of non-metastatic pancreatic cancer. CAN-2409 data sends Candel Th
